M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe
Ask a doctor about a prescription for M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe
How to use M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe
Introduction
Package Leaflet: Information for the User
M-M-RvaxPro
Powder and solvent for suspension for injection in a pre-filled syringe
Measles, mumps and rubella (live virus) vaccine
Read all of this leaflet carefully before you or your child is vaccinated because it contains important information for you or your child.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What M-M-RvaxPro is and what it is used for
- What you need to know before you receive M-M-RvaxPro
- How to use M-M-RvaxPro
- Possible side effects
- Storage of M-M-RvaxPro
- Contents of the pack and other information
1. What M-M-RvaxPro is and what it is used for
M-M-RvaxPro is a vaccine containing weakened viruses of measles, mumps and rubella. When the vaccine is given to a person, the immune system (the body’s natural defences) will create antibodies against the measles, mumps and rubella viruses. The antibodies help protect against infections caused by these viruses.
M-M-RvaxPro is given to help protect you or your child against measles, mumps and rubella. The vaccine can be given to people from 12 months of age onwards.
M-M-RvaxPro can also be given, in special circumstances, to children from 9 to 12 months of age.
M-M-RvaxPro may also be used during measles outbreaks, for post-exposure vaccination, or for use in people over 9 months of age who have not been previously vaccinated and are in contact with susceptible pregnant women, and people who are likely to be susceptible to mumps and rubella.
Although M-M-RvaxPro contains live viruses, they are too weak to cause measles, mumps or rubella in healthy individuals.
2. What you need to know before you receive M-M-RvaxPro
Do not use M-M-RvaxPro
Warnings and precautions
Tell your doctor or pharmacist before the person to be vaccinated receives M-M-RvaxPro if they have:
- had an allergic reaction to egg or any egg-containing product.
- a personal or family history of allergies or convulsions (fits).
- had a side effect after measles, mumps and/or rubella vaccination that involved bruising or bleeding more than usual.
- HIV infection without symptoms of HIV disease. The person to be vaccinated should be closely monitored during and after measles, mumps and rubella vaccination, which may be less effective than for uninfected individuals (see section Do not use M-M-RvaxPro).
As with other vaccines, M-M-RvaxPro may not completely protect all people who are vaccinated. Also, if the person to be vaccinated has already been exposed to measles, mumps or rubella virus but has not yet developed the disease, M-M-RvaxPro may not be able to prevent the disease from appearing.
M-M-RvaxPro can be given to people who have recently (within the last 3 days) been in contact with a case of measles and may be incubating the disease. However, in these cases, M-M-RvaxPro may not be able to prevent the development of measles.
Using M-M-RvaxPro with other medicines
Tell your doctor or pharmacist if the person to be vaccinated is using or has recently used other medicines (or other vaccines).
Your doctor may delay vaccination for at least 3 months after a blood or plasma transfusion or after the administration of immunoglobulin (known as Ig). After vaccination with M-M-RvaxPro, Ig should not be given for 1 month unless your doctor tells you otherwise.
If a tuberculin test is to be done, it should be done at any time before, at the same time as, or from 4 to 6 weeks after vaccination with M-M-RvaxPro.
M-M-RvaxPro can be given with a pneumococcal conjugate vaccine and/or a hepatitis A vaccine at the same time in different injection sites (e.g. the other arm or leg).
M-M-RvaxPro can be given with some routine infant vaccines as they may need to be given at the same time. For vaccines that cannot be given at the same time, M-M-RvaxPro should be given 1 month before or after administration of these vaccines.
Pregnancy and breast-feeding
M-M-RvaxPro should not be given to pregnant women. Women of childbearing age, after being vaccinated, should take precautions to avoid pregnancy for 1 month, or as advised by their doctor.
Tell your doctor if you are breast-feeding or are going to start breast-feeding. Your doctor will decide whether you should receive M-M-RvaxPro.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before receiving this vaccine.
Driving and using machines
There is no information to suggest that M-M-RvaxPro affects the ability to drive or use machines.
M-M-RvaxPro contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.
M-M-RvaxPro contains potassium
This medicine contains potassium, less than 1 mmol (39 mg) per dose; i.e. essentially “potassium-free”.
M-M-RvaxPro contains sorbitol (E-420)
This medicine contains 14.5 mg of sorbitol per dose. The additive effect of medicines containing sorbitol (or fructose) administered concomitantly and the intake of sorbitol (or fructose) from the diet should be taken into account.
3. How to use M-M-RvaxPro
M-M-RvaxPro should be injected into the muscle or under the skin in the outer aspect of the thigh or upper arm. For intramuscular injections, the thigh is the recommended site in young children, while the upper arm is the recommended site in older individuals. M-M-RvaxPro should not be injected into any blood vessel.
M-M-RvaxPro should be administered as follows:
A single dose on the selected date, normally from 12 months of age onwards. In special circumstances, it can be given from 9 months of age onwards. Additional doses should be administered according to the doctor’s recommendations. The interval between 2 doses should be at least 4 weeks.
Instructions for reconstitution intended for medical or healthcare professionals are included at the end of the package leaflet.
4. Possible side effects
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
The following side effects were reported with the use of M-M-RvaxPro:
Frequency | Side effects |
Very common (may affect more than 1 in 10 people) |
|
Common (may affect up to 1 in 10 people) |
|
Uncommon (may affect up to 1 in 100 people) |
|
Frequency not known (cannot be estimated from the available data)* |
|
- These side effects were reported with the administration of both M-M-RvaxPro and the measles, mumps and rubella vaccine manufactured by MSD as well as their monovalent (individual) components during post-marketing use and/or during clinical trials.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of M-M-RvaxPro
Keep out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the outer packaging after EXP. The expiry date refers to the last day of that month.
Store and transport refrigerated (between 2°C and 8°C).
Store the powder vial in the outer packaging to protect from light.
Do not freeze the vaccine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Container contents and additional information
M-M-RvaxPro composition
The active ingredients are:
After reconstitution, a dose (0.5 ml) contains:
Measles virus1 Enders’ Edmonston strain (live, attenuated) not less than 1 x 10^3 TCID50*
Mumps virus1 Jeryl Lynn strain [Level B] (live, attenuated) not less than 12.5 x 10^3 TCID50*
Rubella virus2 Wistar RA 27/3 strain (live, attenuated) not less than 1 x 10^3 TCID50*
- Dose that infects 50% of tissue cultures.
1 Produced in chicken embryo cells.
2 Produced in human diploid lung fibroblasts (WI-38).
The other components are:
Powder:
Sorbitol (E-420), sodium phosphate (NaH2PO4/Na2HPO4), potassium phosphate (KH2PO4/K2HPO4), sucrose, hydrolyzed gelatin, 199 medium with Hanks' salts, MEM, monosodium L-glutamate, neomycin, phenol red, sodium bicarbonate (NaHCO3), hydrochloric acid (HCl) (for pH adjustment) and sodium hydroxide (NaOH) (for pH adjustment).
Solvent:
Water for injections.
Appearance of M-M-RvaxPro and container contents
The vaccine is a powder for injectable suspension contained in a single-dose vial, which must be mixed with the supplied solvent.
The solvent is a clear, colorless liquid. The powder is a compact, crystalline mass of pale yellow color.
M-M-RvaxPro is available in packs of 1, 10, and 20, with or without needles. Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Netherlands
For further information about this medicinal product, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 | Lietuva UAB Merck Sharp & Dohme Tel. +370 5 2780 247 |
| Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 |
Ceská republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 | Magyarország MSD Pharma Hungary Kft. Tel.: + 36.1.888.5300 |
Danmark MSD Danmark ApS Tlf.: + 45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558) |
Deutschland MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Eesti Merck Sharp & Dohme OÜ Tel.: +372 6144 200 | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 |
Ελλάδα MSD Α.Φ.Ε.Ε. Τηλ: +30 210 98 97 300 | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Polska MSD Polska Sp. z o.o. Tel.: +48 22 549 51 00 |
France MSD France Tél: + 33 (0)1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: +385 1 66 11 333 | România Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386.1.520.4201 |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 |
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 650 |
Κύπρος Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700) | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvija SIA Merck Sharp & Dohme Latvija Tel.: +371 67025300 | United Kingdom(Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 |
Date of last revision of this leaflet:<{MM/AAAA}><{month AAAA}>.
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website https://www.ema.europa.eu.
---------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Before mixing with the solvent, the vaccine powder is a compact, crystalline mass of pale yellow color. The solvent is a clear, colorless liquid. When fully reconstituted, the vaccine is a clear yellow liquid.
For reconstitution of the vaccine, use the supplied solvent.
It is important to use a new sterile syringe and needle for each patient in order to prevent the transmission of infectious agents from one person to another.
A separate needle should be used for reconstitution and a different needle for injection.
Reconstitution instructions
To attach the needle, place it firmly on the syringe and secure it with a twist.
Inject the entire contents of the solvent from the syringe into the vial containing the powder. Gently swirl to mix completely.
The reconstituted vaccine should not be used if any foreign particles are observed or if the appearance of the solvent or powder or reconstituted vaccine differs from that described above.
After reconstitution, it is recommended to administer the vaccine immediately to minimize loss of potency or within 8 hours if stored in the refrigerator.
Do not freeze the reconstituted vaccine.
Withdraw the entire contents of the reconstituted vaccine from the vial into a syringe, change the needle, and inject the entire contents subcutaneously or intramuscularly.
Unused products or waste materials should be disposed of in accordance with local requirements.
See also section 3. How to use M-M-RvaxPro.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled SyringeDosage form: INJECTABLE, 1 MILES DICT50 VIRUS / 0.01 MILES DICT50 VIRUS / 12.5 MILES DICT50 VIRUSActive substance: measles, combinations with mumps and rubella, live attenuatedManufacturer: Merck Sharp & Dohme B.V.Prescription requiredDosage form: INJECTABLE, 0.5 mlActive substance: measles, combinations with mumps and rubella, live attenuatedManufacturer: Glaxosmithkline S.A.Prescription requiredDosage form: INJECTABLE, 3 Infectious dose 50% in tissue culture / 3 Infectious dose 50% in tissue culture / 4.3 Infectious dose 50% in tissue culture / 3.99 FIP UActive substance: measles, combinations with mumps, rubella and varicella, live attenuatedManufacturer: Merck Sharp & Dohme B.V.Prescription required
Alternatives to M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe in Poland
Alternative to M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe in Ukraine
Online doctors for M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for M-M-RVAXPRO Powder and Solvent for Injectable Suspension in Pre-filled Syringe – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
